

# About Us



WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing company serving the life sciences industry with operations across Asia, North America, and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), we offer our worldwide partners efficient, flexible, and high-quality specialized services in drug discovery, development, and manufacturing to enable our clients to bring more innovative drugs to market faster.

## Our Vision

Every drug can be made and every disease can be treated.

Enabler of Innovation

Trusted Partner

Global Contributor

## Global Research, Development, and Manufacturing Network

China



**Shanghai Waigaoqiao**  
 • API Process Development  
 • Formulation Development and Manufacturing



**Shanghai Jinshan**  
 API Process Development and Manufacturing



**Changzhou, Jiangsu**  
 API Process Development and Manufacturing (Small molecule, oligo and peptide)



**Wuxi city, Jiangsu**  
 Formulation Development and Manufacturing



**Changshu, Jiangsu**  
 Early Intermediate Manufacturing



**Taixing, Jiangsu**  
 API Process Development and Manufacturing (Small molecule, oligo and peptide)



**Taixing, Jiangsu**  
 Early Intermediate Manufacturing



**Tianjin**  
 • API Process Development  
 • Discovery Oligonucleotide, Amidite, GalNac



**Wuhan, Hubei**  
 • API Process Development  
 • Peptide Discovery and Research



**Sichuan, Chengdu**  
 • Unnatural Amino Acid Synthesis  
 • Peptide Synthesis

USA



**San Diego, CA**  
 • API Process Development and Manufacturing  
 • Formulation Development and Manufacturing



**Middletown, DE (2025)**  
 Formulation Development and Manufacturing (Small molecule, oligo and peptide)

Switzerland



**Couvret**  
 Drug Product Manufacturing

Singapore



**Singapore (2026)**  
 API Process Development and Manufacturing (Small molecule, oligo and peptide)

## Exemplary Quality Record



**11** US FDA  
2013 - 2023



**4** EMA  
2019 - 2022



**4** SwissMedic  
2018 - 2022



**6** Japan PMDA  
2019 - 2022



**4** South Korea MFDS  
2022



**52** China NMPA  
2015 - 2023



**300+** client audits every year

## 10+ Global ESG Recognitions

**2<sup>nd</sup>**

Place in the entire global CXO industry (2022)



Member of **Dow Jones Sustainability Indices**  
 Powered by the S&P Global CSA



**Top 1** in global CXO industry



At WuXi STA, our commitment to ESG principles is integral to our role as a responsible global citizen. We uphold the highest standards in environmental health and safety at all our facilities. Our dedication, however, goes beyond global standards. We are advocates of continuous improvements in waste and water treatment, green chemistries – from process design to solvent reduction, biocatalysis and flow chemistry – and we ensure our employees are protected by the most stringent safety protocols in the industry.

GHG Reduction Target

**30%** ↓  
GHG intensity reduction

Energy-saving Target

**25%** ↓  
energy consumption intensity reduction

Water-saving Target

**45%** ↓  
water consumption intensity reduction

Waste Management Target

**Be landfill-free**  
for all productive hazardous wastes

**Our Environmental Targets by 2030**

### Research Chemistry

Medicinal Chemistry, Library and Custom Synthesis, Catalog Products, Discovery Process Chemistry

### Small Molecule API


Process Development, Manufacturing

### Drug Product

Solid State, Pre-formulation, Formulation, Manufacturing, Packaging, Labeling, Distribution

### WuXi TIDES


Oligonucleotides, Peptides, Conjugates, Amidites, Unnatural Amino Acids, Linkers, Ligands



## Industry Leading Enabling Technology Platform




Crystallization & Particle Engineering




Biocatalysis



Chemo Catalysis



Continuous Manufacturing



Preparative HPLC and SFC



Spray Dried Dispersion




Hot Melt Extrusion



Nano Suspension



Liquid Capsules



Lipid Nanoparticle

### By the Numbers

# 13,260

employees worldwide  
(by December 2023)

# 1,294

global customers served in 2023

# 105

country approvals for marketed drugs

### Commitment to Excellence

**10** times  
2012-2024



**CDMO LEADERSHIP AWARDS**

by Life Science Leader

Capabilities | Compatibility | Expertise | Quality | Reliability | Service

# 190

Client Awards  
(since 2011)



✉ [STA\\_info@wuxiapptec.com](mailto:STA_info@wuxiapptec.com)

🌐 [www.stapharma.com](http://www.stapharma.com)



Follow us on LinkedIn